The certification confirms Renuva’s compliance with the EU’s updated medical device standards for treating acne scars and striae.
Wingderm announced that its Renuva 1550nm non-ablative fractional laser system has obtained Medical Device Regulation (MDR) certification in the European Union (EU). Renuva is certified under MDR for treating acne scars and striae across Fitzpatrick skin types I to VI.
Before this approval, Renuva already held Medical Device Directive (MDD) certification in the EU. Moving from MDD to MDR reflects compliance with the latest regulatory standards for medical devices.
Renuva utilizes fractional photothermolysis technology, delivering controlled energy into micro-areas of the skin while preserving surrounding tissue. This approach aims to enhance the skin’s appearance, supporting a comfortable and minimally interruptive beauty experience. Renuva is designed for professional settings and to allow clients to resume their daily activities with minimal interruption. Renuva procedures can be adjusted according to professional guidance for safe operation on different skin types.
“Renuva can be combined with other aesthetic procedures or used on its own within a treatment program. Individuals typically resume normal activities soon after each session, with the experience being described as well-tolerated,” says Dr Martyn King, vice-chair of the Joint Council of Cosmetic Practitioners and member of the British College of Aesthetic Medicine, in a release. “Renuva treatment is frequently chosen by male clients, as the experience is generally described as comfortable, with limited disruption to daily life.”
Renuva’s MDR certification reinforces its market position and provides clinics with a regulated, technology-based option for professional aesthetic programs.
Photo caption: 1550nm non-ablative fractional laser system
Photo credit: Wingderm
